Larvol Delta - Phase-3-Study-to-Assess-the-Efficacy-and-Safety-of-Batoclimab-as-Induction-and-Maintenance-Therapy-in-Adult-Participants-With-Generalized-Myasthenia-Gravis

batoclimab (HBM9161) - Harbour BioMed, Immunovant, HanAll Biopharma

http://clinicaltrials.gov/ct2/show/NCT05403541

Sep 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next